Most Read Articles
Pearl Toh, 6 days ago
The tyrosine kinase inhibitor nintedanib significantly delayed progression of a wide range of fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) compared with placebo, according to the INBUILD* study presented at ERS 2019.
15 Jul 2018
New drug applications approved by US FDA as of 1 - 15 July 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.

Cardiac biomarkers pinpoint CAP patients at high risk of adverse CV events

20 Aug 2019

Cardiac biomarkers are useful for identifying community-acquired pneumonia (CAP) patients with an elevated risk of early and long-term cardiovascular (CV) events, according to a study.

Researchers followed 730 hospitalized CAP patients for 1 year. They measured several cardiovascular (proadrenomedullin [proADM], pro b-type natriuretic peptide [proBNP], proendothelin-1, and troponin T) and inflammatory biomarkers (interleukin 6 [IL-6], C-reactive protein [CRP] and procalcitonin [PCT]) at several time points (days 1, 4/5 and 30), exploring their utility for assessing early (within 30 days) or long-term (1 year follow-up) CV events.

A total of 92 patients developed an early CV event and 67 a long-term event. Patients who did vs did not develop CV events had markedly higher initial levels of proADM, proendothelin-1, troponin, proBNP and IL-6. Despite a drop at day 4/5, levels remained quite steady until day 30 in those who developed late events.

On multivariable regression analysis, several days 1 and 30 biomarkers independently predicted CV events, as follows: proendothelin-1 (odds ratio [OR], 2.25, 95 percent CI, 1.34–3.79), proADM (OR, 2.53, 1.53–4.20), proBNP (OR, 2.67, 1.59–4.49) and troponin T (OR, 2.70, 1.62–4.49) for early events, and proendothelin-1 (OR, 3.13, 1.41–7.80), proADM (OR, 2.29, 1.01–5.19) and proBNP (OR, 2.34, 1.01–5.56) for late events.

Furthermore, the addition of IL-6 levels at day 30 to proendothelin-1 or proADM strengthened these cardiac biomarkers’ association with late CV events (ORs, 3.53 and 2.80, respectively).

The findings highlight the usefulness of cardiac biomarkers, potentially aiding personalized treatment optimization and facilitating design of future interventional studies to reduce CV risk, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
The tyrosine kinase inhibitor nintedanib significantly delayed progression of a wide range of fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) compared with placebo, according to the INBUILD* study presented at ERS 2019.
15 Jul 2018
New drug applications approved by US FDA as of 1 - 15 July 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.